BR0012793A - Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina - Google Patents

Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina

Info

Publication number
BR0012793A
BR0012793A BR0012793-0A BR0012793A BR0012793A BR 0012793 A BR0012793 A BR 0012793A BR 0012793 A BR0012793 A BR 0012793A BR 0012793 A BR0012793 A BR 0012793A
Authority
BR
Brazil
Prior art keywords
nicotine
methods
receptor agonist
another
administering
Prior art date
Application number
BR0012793-0A
Other languages
English (en)
Inventor
John Cooke
James Jang
Phillip Tsao
Christopher Heeschen
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR0012793A publication Critical patent/BR0012793A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

"MéTODOS PARA INDUçãO DE ANGIOGêNESE PELA ADMINISTRAçãO DE NICOTINA OU OUTRO AGONISTA DE RECEPTOR DE NICOTINA". A presente invenção apresenta métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina. A indução de angiogênese pelos métodos da invenção pode ser usada na angiogênese terapêutica em, por exemplo, tratamento de síndromes isquêmicas tais como doença arterial coronariana ou periférica. A figura é um gráfico que ilustra o efeito da nicotina administrada por via intramuscular sob densidade capilar em um modelo animal de isquemia.
BR0012793-0A 1999-07-28 2000-07-28 Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina BR0012793A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14623399P 1999-07-28 1999-07-28
PCT/US2000/020751 WO2001008684A1 (en) 1999-07-28 2000-07-28 Nicotine in therapeutic angiogenesis and vasculogenesis

Publications (1)

Publication Number Publication Date
BR0012793A true BR0012793A (pt) 2002-04-30

Family

ID=22516426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012793-0A BR0012793A (pt) 1999-07-28 2000-07-28 Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina

Country Status (12)

Country Link
US (2) US6417205B1 (pt)
EP (1) EP1202736B1 (pt)
JP (2) JP2003505507A (pt)
AT (1) ATE408406T1 (pt)
AU (1) AU781084B2 (pt)
BR (1) BR0012793A (pt)
CA (1) CA2380072C (pt)
DE (1) DE60040293D1 (pt)
DK (1) DK1202736T3 (pt)
ES (1) ES2313900T3 (pt)
PT (1) PT1202736E (pt)
WO (1) WO2001008684A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US20020192198A1 (en) * 1998-04-21 2002-12-19 Elia James P. Method for growing human organs and suborgans
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6692520B1 (en) * 1998-12-15 2004-02-17 C. R. Bard, Inc. Systems and methods for imbedded intramuscular implants
BR0012793A (pt) * 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU2001294861A1 (en) * 2000-09-29 2002-04-08 Endovasc Ltd., Inc. Resorbable prosthesis for medical treatment
FR2834039B1 (fr) † 2001-12-21 2004-02-13 Inst Francais Du Petrole Conduite flexible a haute resistance a la compression axiale et sa methode de fabrication
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
WO2004012674A2 (en) * 2002-08-02 2004-02-12 Nutraceutical Development Corporation Development of muscle mass in a mammal
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
EP3138566B1 (en) * 2003-11-17 2022-01-26 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2005117860A1 (en) * 2004-06-03 2005-12-15 Asmacure Ltée Method of treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP2724742B1 (en) 2004-08-18 2017-11-01 Geno LLC Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2006055511A2 (en) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
WO2007075720A2 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US11076772B2 (en) 2007-03-30 2021-08-03 David G. Silverman Method and system enabling photoplethysmograph measurement of volume status
US8961932B2 (en) * 2007-03-30 2015-02-24 David G. Silverman “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity
US9782090B1 (en) 2007-03-30 2017-10-10 David G Silverman Method and system enabling photoplethysmograph measurement of volume status
US9877681B2 (en) 2007-03-30 2018-01-30 David G. Silverman “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity
WO2009097343A1 (en) 2008-01-28 2009-08-06 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
WO2010033916A1 (en) * 2008-09-22 2010-03-25 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
AU2010263098B2 (en) 2009-06-22 2016-01-07 VERO Biotech LLC. Nitric oxide therapies
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
WO2019200411A1 (en) * 2018-04-13 2019-10-17 The Administrators Of The Tulaneeducational Fund Biomimetic tissue systems and methods of using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8330969D0 (en) 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3645036A1 (de) 1986-11-18 1989-01-05 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
JPH06504041A (ja) * 1990-11-14 1994-05-12 ユー・エー・ビー・リサーチ　ファウンデーション 虚血性傷害を減少させる方法と組成
JPH0641070A (ja) * 1992-03-23 1994-02-15 Sankyo Co Ltd インドール誘導体
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5318957A (en) 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5508030A (en) 1993-08-05 1996-04-16 Bierman; Howard R. Creating new capillary blood pools for practicing bidirectional medicine
DE4414569A1 (de) * 1994-04-27 1995-11-02 Bayer Ag Verwendung von substituierten Aminen zur Behandlung von Hirnleistungsstörungen
JPH08143454A (ja) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH09124593A (ja) * 1995-08-25 1997-05-13 Ono Pharmaceut Co Ltd プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
EA003190B1 (ru) 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Азаполициклические соединения, конденсированные с арилом
AU1214900A (en) * 1998-10-20 2000-05-08 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR0012793A (pt) * 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
AT409219B (de) 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln

Also Published As

Publication number Publication date
DE60040293D1 (de) 2008-10-30
JP2003505507A (ja) 2003-02-12
ATE408406T1 (de) 2008-10-15
CA2380072C (en) 2007-07-10
DK1202736T3 (da) 2008-12-15
US6417205B1 (en) 2002-07-09
US7160904B2 (en) 2007-01-09
WO2001008684A1 (en) 2001-02-08
ES2313900T3 (es) 2009-03-16
EP1202736A4 (en) 2004-05-19
EP1202736A1 (en) 2002-05-08
CA2380072A1 (en) 2001-02-08
AU6503200A (en) 2001-02-19
US20020128294A1 (en) 2002-09-12
PT1202736E (pt) 2008-12-29
AU781084B2 (en) 2005-05-05
JP2010043094A (ja) 2010-02-25
EP1202736B1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
BR0012793A (pt) Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
DE60027564D1 (de) Tek-antagonisten
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
DK1305286T3 (da) Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
DK1920773T3 (da) Thalidomid og dexamethason til behandling af tumorer
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
NO20062050L (no) Terapeutiske kombinasjoner av antihypertensive og antiangiogene midler
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
SE9800836D0 (sv) New Compounds
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DK0846173T3 (da) Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
RS71404A (en) 1-phenil-2-heteroaryl substitated benzimidazol derivatives, their use for roducing drugs and other pharmaceutical preparations comprising these derivatives
ATE74505T1 (de) Schmerzpraeparat.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.